inMMyCAR
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 70 patients (estimated)
- Tags
- CAR T Cell, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 2212
- NCT Identifier
- NCT07075185
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.